MD NewslineCOVID-19 Vaccines and NMOSD and MS Risk

Examining the Impact of COVID-19 Vaccines on NMOSD and MS Incidence Among Genetically Susceptible Individuals

As the global community continues to battle the ongoing effects of the COVID-19 pandemic, a systematic review in the Revue Neurologique explores the potential relationship between COVID-19 vaccinations and the incidence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Focusing on genetically susceptible individuals, the review looks into the mechanisms and reported cases post-vaccination, contributing valuable insights for medical professionals monitoring long-term vaccine effects.

Key Points:

• Genetic Susceptibility and Vaccination Risks: The review suggests that COVID-19 may slightly increase the risk of NMOSD and MS, predominantly in genetically susceptible individuals.
• Overview of NMOSD and MS: NMOSD is an autoimmune condition often associated with antibodies against aquaporin-4, while MS is a central nervous system disorder characterized by axonal damage.
• Systematic Review Findings: Out of 954 studies, only 12 reported cases of NMOSD or MS following COVID-19 vaccination, indicating a relatively rare occurrence.
• Incidence Timeline: Symptoms typically manifested within 7.5 days after the first vaccine dose and 15.1 days after the second, underscoring a potential link to vaccination timing.
• Treatment and Recovery: A majority of reported cases were managed effectively with treatments like methylprednisolone infusion and plasma exchange, with all patients recovering.
• Mechanisms of Risk Increase: Possible mechanisms include molecular mimicry and cytokine production triggered by the vaccine, which may elevate the risk in susceptible individuals.
• Comparative Vaccine Data: Similar risks have been observed with vaccines for other viruses, including hepatitis, yellow fever, and influenza, suggesting a broader pattern of immune response challenges.
• Study Limitations and Call for Further Research: The low number of cases and the study’s limitations highlight the need for continued research to better understand these risks.

The prevalence of NMOSD is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry.

More on MS